- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02778802
Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post BLVR
Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post Bronchoscopic Volume Reduction by Histoacryl or Silver Nitrate (Single Center Experince )
This study is designed as a prospective study, with the primary endpoint being changes in pulmonary hemodynamic parameters after ELVR in patients with severe emphysema.
Secondary endpoints will be changes in lung function parameters, exercise capacity, and QoL.
Studienübersicht
Status
Detaillierte Beschreibung
Chronic obstructive pulmonary disease (COPD) continues to be a leading cause of morbidity and is currently the third most common cause of mortality worldwide (1).
In most patients with severe COPD, chronic airflow limitation, lung emphysema with parenchymal destruction and the development of air bullae also occur (2-3) Pulmonary hypertension (PH) is a common consequence of COPD, although the actual overall prevalence of PH in COPD remains unclear (4). Among COPD patients who were to undergo lung-volume-reduction surgery or lung transplantation, mild PH was observed in 50.2%, moderate PH in 9.8%, and severe PH in 3.7%(5). While in most COPD patients who develop PH, pulmonary arterial pressure is only mildly or moderately elevated, (6) PH has an independent prognostic impact on survival. (6,7) The therapeutic options for COPD patients with severe emphysema are limited. Lung volume reduction surgery (LVRS) has been performed as treatment in selected cases, but the referral of patients has been severely influenced by the marked perioperative morbidity and mortality [8]. Less invasive techniques have been developed with the aim of improving patients' pulmonary function, symptoms, and quality of life (QoL) [9]. Among them, the one most commonly used is the endoscopic placement of one way endobronchial valves (EBV) [10-12]. So far patients with severe emphysema and established PH have been excluded from LVRS as well as from endoscopic lung volume reduction (ELVR) therapy.
Whether bronchoscopic lung volume reduction in COPD patients with silver nitrate or histoacryl influences the severity of PH in patients with severe emphysema and PH has yet to be elucidated.
This study is designed as a prospective pilot study, with the primary endpoint being changes in pulmonary hemodynamic parameters after ELVR in patients with severe emphysema.
Secondary endpoints will be changes in lung function parameters, exercise capacity, and QoL.
Materials and Methods This is Prospective descriptive study on 20 COPD Patients with predominant emphysema especially with heterogeneous and upper lobe predominance emphysema admitted in chest department at Kasr al Ainy Hospital. All patients will be on optimal medical treatment for COPD according to Global Initiative for Chronic Obstructive Lung Disease guidelines [13] All patients will be subjected to the following at base line.
- full history taking.
- full clinical examination.
- plain chest x ray.
- an electrocardiogram, High resolution computed tomography of the chest.
- Pulmonary function tests and ABG.
- 6-minute walk test.
- 2-D echocardiography at rest
- Right heart catheterization (RHC)
- Fiberoptic bronchoscopy with application of silver nitrate or histoacryl. The patients will be followed up every month by
1. Dyspnea score (using mMRC score) 2. 6-minute walk test. 3. ECG At 3rd Month 2-D echocardiography at rest will be done At 6th Month 2-D echocardiography at rest And RHC will be done .
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Ahmed M Abd El-Fattah, MSc
- Telefonnummer: 00201003655626
- E-Mail: a.house2012@yahoo.com
Studienorte
-
-
-
Cairo, Ägypten, 14211
- Rekrutierung
- Kasr Alaini School of Medicine
-
Hauptermittler:
- Mostafa Elshazly, MD
-
Unterermittler:
- Mohamed Alnady, MD
-
Unterermittler:
- Karim Mahmoud, MD
-
Unterermittler:
- Ahmed Amer, MSc
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- COPD patients with predominant emphysema especially with heterogeneous and upper lobe predominance emphysema
Exclusion Criteria:
- Airflow limitation with FEV1 < 20%.
- Patients not candidate for FOB.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
change in mean Pulmonary artery pressure after ELVR
Zeitfenster: 3months, 6monthes
|
Right heart cathetrization
|
3months, 6monthes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Dysnea Score
Zeitfenster: 3 months,6months
|
using modified Medical Research Council (mMRC) criteria, with 0 representing dyspnea with strenuous exercise and 4 representing dyspnea with breathlessness when dressing
|
3 months,6months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Mohamed A Elnady, MD, Professor of pulmonary Medicine ,Cairo University
- Studienleiter: Karim Mahmoud, MD, Lecturer of cardiology ,Cairo University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Cairo2002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Pulmonale Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich